Difference between revisions of "Daunorubicin liposomal (DaunoXome)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| + | Also known as daunorubicin citrate liposome injection. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.<ref name="insert">[http://www.gilead.com/pdf/daxpius.pdf Daunorubicin liposomal (DaunoXome) package insert]</ref><ref>[ | + | Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.<ref name="insert">[http://www.gilead.com/pdf/daxpius.pdf Daunorubicin liposomal (DaunoXome) package insert]</ref><ref>[[Media:Daunorubicinliposomal.pdf | Daunorubicin liposomal (DaunoXome) package insert (locally hosted backup)]]</ref><ref>[http://daunoxome.com DaunoXome manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| Line 7: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http:// | + | *[http://chemocare.com/chemotherapy/drug-info/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Anthracyclines]] | ||
| + | [[Category:Topoisomerase inhibitors]] | ||
Revision as of 18:13, 14 October 2012
Also known as daunorubicin citrate liposome injection.
General information
Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)[4]
- Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)[5]
References
- ↑ 1.0 1.1 Daunorubicin liposomal (DaunoXome) package insert
- ↑ Daunorubicin liposomal (DaunoXome) package insert (locally hosted backup)
- ↑ DaunoXome manufacturer's website
- ↑ Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)
- ↑ Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)